> id: https://www.nature.com/articles/s41588-025-02253-8

> link: https://www.nature.com/articles/s41588-025-02253-8

> title: Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma

# Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma
_Published on Mon, 21 Jul 2025 00:00:00 GMT_

Abstract
--------

Radiotherapy resistance and immune evasion are prominent features of recurrent nasopharyngeal carcinoma (rNPC). However, their mechanisms remain incompletely understood. Here, we conducted single-cell and spatial transcriptomics analysis of 39 tumors from 24 patients to reveal the microenvironmental differences between primary and rNPC. Specific MCAM+ cancer-associated fibroblasts are significantly enriched in rNPC, where they promote tumor radioresistance through the collagen IV–ITGA2–FAK–AKT axis. Furthermore, we found that collagen IV suppresses the infiltration of T cells, and we identified mechanisms of immune escape in rNPC. We uncovered the presence and function of CD8 ZNF683 cells in rNPC with lower cytotoxicity. The abundance of B cells and tertiary lymphoid structures significantly diminishes in rNPC. Finally, we confirmed that CD47–SIRPα commonly existed between myeloid and malignant cells in rNPC. This study provides an in-depth understanding of the mechanism of radioresistance and immune evasion in rNPC as well as highlighting critical preliminary targets for curing rNPC.

/\* style specs start \*/ /\* style specs end \*/

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$32.99 / 30 days

cancel any time

[Learn more](https://shop-amers.nature.com/products/plus/?region=US)

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

[Learn more](https://www.nature.com/ng/subscribe)

Buy this article

-   Purchase on SpringerLink
-   Instant access to full article PDF

[Buy now](https://link.springer.com/article/10.1038/s41588-025-02253-8?utm_source=nature&utm_medium=referral&utm_campaign=buyArticle)

Prices may be subject to local taxes which are calculated during checkout

/\* style specs start \*/ style { display: none !important; } .LiveAreaSection \* { align-content: stretch; align-items: stretch; align-self: auto; animation-delay: 0s; animation-direction: normal; animation-duration: 0s; animation-fill-mode: none; animation-iteration-count: 1; animation-name: none; animation-play-state: running; animation-timing-function: ease; azimuth: center; backface-visibility: visible; background-attachment: scroll; background-blend-mode: normal; background-clip: borderBox; background-color: transparent; background-image: none; background-origin: paddingBox; background-position: 0 0; background-repeat: repeat; background-size: auto auto; block-size: auto; border-block-end-color: currentcolor; border-block-end-style: none; border-block-end-width: medium; border-block-start-color: currentcolor; border-block-start-style: none; border-block-start-width: medium; border-bottom-color: currentcolor; border-bottom-left-radius: 0; border-bottom-right-radius: 0; border-bottom-style: none; border-bottom-width: medium; border-collapse: separate; border-image-outset: 0s; border-image-repeat: stretch; border-image-slice: 100%; border-image-source: none; border-image-width: 1; border-inline-end-color: currentcolor; border-inline-end-style: none; border-inline-end-width: medium; border-inline-start-color: currentcolor; border-inline-start-style: none; border-inline-start-width: medium; border-left-color: currentcolor; border-left-style: none; border-left-width: medium; border-right-color: currentcolor; border-right-style: none; border-right-width: medium; border-spacing: 0; border-top-color: currentcolor; border-top-left-radius: 0; border-top-right-radius: 0; border-top-style: none; border-top-width: medium; bottom: auto; box-decoration-break: slice; box-shadow: none; box-sizing: border-box; break-after: auto; break-before: auto; break-inside: auto; caption-side: top; caret-color: auto; clear: none; clip: auto; clip-path: none; color: initial; column-count: auto; column-fill: balance; column-gap: normal; column-rule-color: currentcolor; column-rule-style: none; column-rule-width: medium; column-span: none; column-width: auto; content: normal; counter-increment: none; counter-reset: none; cursor: auto; display: inline; empty-cells: show; filter: none; flex-basis: auto; flex-direction: row; flex-grow: 0; flex-shrink: 1; flex-wrap: nowrap; float: none; font-family: initial; font-feature-settings: normal; font-kerning: auto; font-language-override: normal; font-size: medium; font-size-adjust: none; font-stretch: normal; font-style: normal; font-synthesis: weight style; font-variant: normal; font-variant-alternates: normal; font-variant-caps: normal; font-variant-east-asian: normal; font-variant-ligatures: normal; font-variant-numeric: normal; font-variant-position: normal; font-weight: 400; grid-auto-columns: auto; grid-auto-flow: row; grid-auto-rows: auto; grid-column-end: auto; grid-column-gap: 0; grid-column-start: auto; grid-row-end: auto; grid-row-gap: 0; grid-row-start: auto; grid-template-areas: none; grid-template-columns: none; grid-template-rows: none; height: auto; hyphens: manual; image-orientation: 0deg; image-rendering: auto; image-resolution: 1dppx; ime-mode: auto; inline-size: auto; isolation: auto; justify-content: flexStart; left: auto; letter-spacing: normal; line-break: auto; line-height: normal; list-style-image: none; list-style-position: outside; list-style-type: disc; margin-block-end: 0; margin-block-start: 0; margin-bottom: 0; margin-inline-end: 0; margin-inline-start: 0; margin-left: 0; margin-right: 0; margin-top: 0; mask-clip: borderBox; mask-composite: add; mask-image: none; mask-mode: matchSource; mask-origin: borderBox; mask-position: 0 0; mask-repeat: repeat; mask-size: auto; mask-type: luminance; max-height: none; max-width: none; min-block-size: 0; min-height: 0; min-inline-size: 0; min-width: 0; mix-blend-mode: normal; object-fit: fill; object-position: 50% 50%; offset-block-end: auto; offset-block-start: auto; offset-inline-end: auto; offset-inline-start: auto; opacity: 1; order: 0; orphans: 2; outline-color: initial; outline-offset: 0; outline-style: none; outline-width: medium; overflow: visible; overflow-wrap: normal; overflow-x: visible; overflow-y: visible; padding-block-end: 0; padding-block-start: 0; padding-bottom: 0; padding-inline-end: 0; padding-inline-start: 0; padding-left: 0; padding-right: 0; padding-top: 0; page-break-after: auto; page-break-before: auto; page-break-inside: auto; perspective: none; perspective-origin: 50% 50%; pointer-events: auto; position: static; quotes: initial; resize: none; right: auto; ruby-align: spaceAround; ruby-merge: separate; ruby-position: over; scroll-behavior: auto; scroll-snap-coordinate: none; scroll-snap-destination: 0 0; scroll-snap-points-x: none; scroll-snap-points-y: none; scroll-snap-type: none; shape-image-threshold: 0; shape-margin: 0; shape-outside: none; tab-size: 8; table-layout: auto; text-align: initial; text-align-last: auto; text-combine-upright: none; text-decoration-color: currentcolor; text-decoration-line: none; text-decoration-style: solid; text-emphasis-color: currentcolor; text-emphasis-position: over right; text-emphasis-style: none; text-indent: 0; text-justify: auto; text-orientation: mixed; text-overflow: clip; text-rendering: auto; text-shadow: none; text-transform: none; text-underline-position: auto; top: auto; touch-action: auto; transform: none; transform-box: borderBox; transform-origin: 50% 50%0; transform-style: flat; transition-delay: 0s; transition-duration: 0s; transition-property: all; transition-timing-function: ease; vertical-align: baseline; visibility: visible; white-space: normal; widows: 2; width: auto; will-change: auto; word-break: normal; word-spacing: normal; word-wrap: normal; writing-mode: horizontalTb; z-index: auto; -webkit-appearance: none; -moz-appearance: none; -ms-appearance: none; appearance: none; margin: 0; } .LiveAreaSection { width: 100%; } .LiveAreaSection .login-option-buybox { display: block; width: 100%; font-size: 17px; line-height: 30px; color: #222; padding-top: 30px; font-family: Harding, Palatino, serif; } .LiveAreaSection .additional-access-options { display: block; font-weight: 700; font-size: 17px; line-height: 30px; color: #222; font-family: Harding, Palatino, serif; } .LiveAreaSection .additional-login > li:not(:first-child)::before { transform: translateY(-50%); content: ""; height: 1rem; position: absolute; top: 50%; left: 0; border-left: 2px solid #999; } .LiveAreaSection .additional-login > li:not(:first-child) { padding-left: 10px; } .LiveAreaSection .additional-login > li { display: inline-block; position: relative; vertical-align: middle; padding-right: 10px; } .BuyBoxSection { display: flex; flex-wrap: wrap; flex: 1; flex-direction: row-reverse; margin: -30px -15px 0; } .BuyBoxSection .box-inner { width: 100%; height: 100%; padding: 30px 5px; display: flex; flex-direction: column; justify-content: space-between; } .BuyBoxSection p { margin: 0; } .BuyBoxSection .readcube-buybox { background-color: #f3f3f3; flex-shrink: 1; flex-grow: 1; flex-basis: 255px; background-clip: content-box; padding: 0 15px; margin-top: 30px; } .BuyBoxSection .subscribe-buybox { background-color: #f3f3f3; flex-shrink: 1; flex-grow: 4; flex-basis: 300px; background-clip: content-box; padding: 0 15px; margin-top: 30px; } .BuyBoxSection .subscribe-buybox-nature-plus { background-color: #f3f3f3; flex-shrink: 1; flex-grow: 4; flex-basis: 100%; background-clip: content-box; padding: 0 15px; margin-top: 30px; } .BuyBoxSection .title-readcube, .BuyBoxSection .title-buybox { display: block; margin: 0; margin-right: 10%; margin-left: 10%; font-size: 24px; line-height: 32px; color: #222; text-align: center; font-family: Harding, Palatino, serif; } .BuyBoxSection .title-asia-buybox { display: block; margin: 0; margin-right: 5%; margin-left: 5%; font-size: 24px; line-height: 32px; color: #222; text-align: center; font-family: Harding, Palatino, serif; } .BuyBoxSection .asia-link, .Link-328123652, .Link-2926870917, .Link-2291679238, .Link-595459207 { color: #069; cursor: pointer; text-decoration: none; font-size: 1.05em; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; line-height: 1.05em6; } .BuyBoxSection .access-readcube { display: block; margin: 0; margin-right: 10%; margin-left: 10%; font-size: 14px; color: #222; padding-top: 10px; text-align: center; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; line-height: 20px; } .BuyBoxSection ul { margin: 0; } .BuyBoxSection .link-usp { display: list-item; margin: 0; margin-left: 20px; padding-top: 6px; list-style-position: inside; } .BuyBoxSection .link-usp span { font-size: 14px; color: #222; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; line-height: 20px; } .BuyBoxSection .access-asia-buybox { display: block; margin: 0; margin-right: 5%; margin-left: 5%; font-size: 14px; color: #222; padding-top: 10px; text-align: center; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; line-height: 20px; } .BuyBoxSection .access-buybox { display: block; margin: 0; margin-right: 10%; margin-left: 10%; font-size: 14px; color: #222; opacity: 0.8px; padding-top: 10px; text-align: center; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; line-height: 20px; } .BuyBoxSection .price-buybox { display: block; font-size: 30px; color: #222; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; padding-top: 30px; text-align: center; } .BuyBoxSection .price-buybox-to { display: block; font-size: 30px; color: #222; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; text-align: center; } .BuyBoxSection .price-info-text { font-size: 16px; padding-right: 10px; color: #222; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; } .BuyBoxSection .price-value { font-size: 30px; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; } .BuyBoxSection .price-per-period { font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; } .BuyBoxSection .price-from { font-size: 14px; padding-right: 10px; color: #222; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; line-height: 20px; } .BuyBoxSection .issue-buybox { display: block; font-size: 13px; text-align: center; color: #222; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; line-height: 19px; } .BuyBoxSection .no-price-buybox { display: block; font-size: 13px; line-height: 18px; text-align: center; padding-right: 10%; padding-left: 10%; padding-bottom: 20px; padding-top: 30px; color: #222; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; } .BuyBoxSection .vat-buybox { display: block; margin-top: 5px; margin-right: 20%; margin-left: 20%; font-size: 11px; color: #222; padding-top: 10px; padding-bottom: 15px; text-align: center; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; line-height: 17px; } .BuyBoxSection .tax-buybox { display: block; width: 100%; color: #222; padding: 20px 16px; text-align: center; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; line-height: NaNpx; } .BuyBoxSection .button-container { display: flex; padding-right: 20px; padding-left: 20px; justify-content: center; } .BuyBoxSection .button-container > \* { flex: 1px; } .BuyBoxSection .button-container > a:hover, .Button-505204839:hover, .Button-1078489254:hover, .Button-2737859108:hover { text-decoration: none; } .BuyBoxSection .btn-secondary { background: #fff; } .BuyBoxSection .button-asia { background: #069; border: 1px solid #069; border-radius: 0; cursor: pointer; display: block; padding: 9px; outline: 0; text-align: center; text-decoration: none; min-width: 80px; margin-top: 75px; } .BuyBoxSection .button-label-asia, .ButtonLabel-3869432492, .ButtonLabel-3296148077, .ButtonLabel-1636778223 { display: block; color: #fff; font-size: 17px; line-height: 20px; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell, "Helvetica Neue", sans-serif; text-align: center; text-decoration: none; cursor: pointer; } .Button-505204839, .Button-1078489254, .Button-2737859108 { background: #069; border: 1px solid #069; border-radius: 0; cursor: pointer; display: block; padding: 9px; outline: 0; text-align: center; text-decoration: none; min-width: 80px; max-width: 320px; margin-top: 20px; } .Button-505204839 .btn-secondary-label, .Button-1078489254 .btn-secondary-label, .Button-2737859108 .btn-secondary-label { color: #069; } .uList-2102244549 { list-style: none; padding: 0; margin: 0; } /\* style specs end \*/

**Fig. 1: ScRNA-seq and spatial profiling of the pNPC and rNPC TME.**

![](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_Fig1_HTML.png)

**Fig. 2: Characteristics of malignant cells in PT and RT samples and their effects on the tumor ecosystem.**

![](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_Fig2_HTML.png)

**Fig. 3: MCAM-positive fibroblasts were identified in rNPC and were found to promote the radioresistance of NPC tumor cells.**

![](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_Fig3_HTML.png)

**Fig. 4: MCAM+ mCAFs promoted the radioresistance of NPC tumor cells through the COL4–ITGA2–FAK–AKT pathway.**

![](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_Fig4_HTML.png)

**Fig. 5: Intratumoral collagen IV levels were correlated with T cell suppression and immune escape in patients with NPC.**

![](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_Fig5_HTML.png)

**Fig. 6: CD8+ T cells maintain a memory phenotype with weak cytotoxicity in rNPC.**

![](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_Fig6_HTML.png)

**Fig. 7: TLSs were depleted in rNPC.**

![](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_Fig7_HTML.png)

**Fig. 8: SIRPα+ myeloid cells reside near CD47+ malignant cells and may inhibit antigen presentation in rNPC.**

![](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_Fig8_HTML.png)

### Similar content being viewed by others

![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41419-022-04904-8/MediaObjects/41419_2022_4904_Fig1_HTML.png)

### [Single-cell characterization of malignant phenotypes and microenvironment alteration in retinoblastoma](https://www.nature.com/articles/s41419-022-04904-8?fromPaywallRec=true)

Article Open access 06 May 2022

![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41419-024-06840-1/MediaObjects/41419_2024_6840_Fig1_HTML.png)

### [Multiomics integration-based immunological characterizations of adamantinomatous craniopharyngioma in relation to keratinization](https://www.nature.com/articles/s41419-024-06840-1?fromPaywallRec=true)

Article Open access 21 June 2024

![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-024-48700-8/MediaObjects/41467_2024_48700_Fig1_HTML.png)

### [Single-cell and spatial transcriptomics analysis of non-small cell lung cancer](https://www.nature.com/articles/s41467-024-48700-8?fromPaywallRec=true)

Article Open access 23 May 2024

Data availability
-----------------

Raw scRNA-seq, spatial transcriptomics and WES data of pNPC and rNPC samples have been deposited in the Genome Sequence Archive of the Beijing Institute of Genomics (BIG) Data Center at the Beijing Institute of Genomics, Chinese Academy of Science, under accession number HRA010466 (accessible at [http://bigd.big.ac.cn/gsa-human](http://bigd.big.ac.cn/gsa-human)). Bulk RNA-seq data of human-NPC cell lines after indicated treatment were downloaded from the GSA-Human database under accession number HRA010688 (accessible at [http://bigd.big.ac.cn/gsa-human](http://bigd.big.ac.cn/gsa-human)). The WES data for 43 RT and 32 PT previously reported by our team are under accession numbers HRA000052 and HRA000053, which can be accessed at [http://bigd.big.ac.cn/gsa-human](http://bigd.big.ac.cn/gsa-human). The bulk RNA-seq data from 88 PT samples reported in a previous publication[26](https://www.nature.com/articles/s41588-025-02253-8#ref-CR26 "Zhang, L. et al. Genomic analysis of nasopharyngeal carcinoma reveals TME-based subtypes. Mol. Cancer Res. 15, 1722–1732 (2017).") are under accession number [GSE102349](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102349). [Source data](https://www.nature.com/articles/s41588-025-02253-8#Sec42) are provided with this paper.

Code availability
-----------------

The custom code used in this study is available at [https://github.com/zhanglabtools/NPC\_scRNA\_Spatial\_code](https://github.com/zhanglabtools/NPC_scRNA_Spatial_code). This repository has been archived at Zenodo ([https://doi.org/10.5281/zenodo.15104454](https://doi.org/10.5281/zenodo.15104454))[78](https://www.nature.com/articles/s41588-025-02253-8#ref-CR78 "You, R. et al. Custom code for study: single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma. Zenodo 
https://doi.org/10.5281/zenodo.15104454
(2025).").

References
----------

1.  Wang, Y. Q. et al. Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: a large-scale cohort study. _Int. J. Cancer_ **142**, 2558–2566 (2018).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29377121)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXisVeks7k%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prognostic%20significance%20of%20tumor-infiltrating%20lymphocytes%20in%20nondisseminated%20nasopharyngeal%20carcinoma%3A%20a%20large-scale%20cohort%20study&journal=Int.%20J.%20Cancer&volume=142&pages=2558-2566&publication_year=2018&author=Wang%2CYQ) 
    
2.  Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. _Cell_ **177**, 1330–1345.e18 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30982598)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526772)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXnt1Clurs%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20single-cell%20atlas%20of%20the%20tumor%20and%20immune%20ecosystem%20of%20human%20breast%20cancer&journal=Cell&volume=177&pages=1330-1345.e18&publication_year=2019&author=Wagner%2CJ) 
    
3.  Xue, R. et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. _Nature_ **612**, 141–147 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36352227)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XivVCks77N)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Liver%20tumour%20immune%20microenvironment%20subtypes%20and%20neutrophil%20heterogeneity&journal=Nature&volume=612&pages=141-147&publication_year=2022&author=Xue%2CR) 
    
4.  Chen, X. & Song, E. The theory of tumor ecosystem. _Cancer Commun. (Lond.)_ **42**, 587–608 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35642770)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20theory%20of%20tumor%20ecosystem&journal=Cancer%20Commun.%20%28Lond.%29&volume=42&pages=587-608&publication_year=2022&author=Chen%2CX&author=Song%2CE) 
    
5.  Chua, M. L. K., Wee, J. T. S., Hui, E. P. & Chan, A. T. C. Nasopharyngeal carcinoma. _Lancet_ **387**, 1012–1024 (2016).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26321262)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Nasopharyngeal%20carcinoma&journal=Lancet&volume=387&pages=1012-1024&publication_year=2016&author=Chua%2CMLK&author=Wee%2CJTS&author=Hui%2CEP&author=Chan%2CATC) 
    
6.  Ng, W. T. et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. _Int. J. Radiat. Oncol. Biol. Phys._ **79**, 420–428 (2011).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20452132)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Clinical%20outcomes%20and%20patterns%20of%20failure%20after%20intensity-modulated%20radiotherapy%20for%20nasopharyngeal%20carcinoma&journal=Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.&volume=79&pages=420-428&publication_year=2011&author=Ng%2CWT) 
    
7.  Zhao, C. et al. Locoregional control and mild late toxicity after reducing target volumes and radiation doses in patients with locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy (IC) followed by concurrent chemoradiotherapy: 10-year results of a phase 2 study. _Int. J. Radiat. Oncol. Biol. Phys._ **104**, 836–844 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30954521)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Locoregional%20control%20and%20mild%20late%20toxicity%20after%20reducing%20target%20volumes%20and%20radiation%20doses%20in%20patients%20with%20locoregionally%20advanced%20nasopharyngeal%20carcinoma%20treated%20with%20induction%20chemotherapy%20%28IC%29%20followed%20by%20concurrent%20chemoradiotherapy%3A%2010-year%20results%20of%20a%20phase%202%20study&journal=Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.&volume=104&pages=836-844&publication_year=2019&author=Zhao%2CC) 
    
8.  You, R. et al. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. _Lancet_ **401**, 917–927 (2023).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36842439)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Hyperfractionation%20compared%20with%20standard%20fractionation%20in%20intensity-modulated%20radiotherapy%20for%20patients%20with%20locally%20advanced%20recurrent%20nasopharyngeal%20carcinoma%3A%20a%20multicentre%2C%20randomised%2C%20open-label%2C%20phase%203%20trial&journal=Lancet&volume=401&pages=917-927&publication_year=2023&author=You%2CR) 
    
9.  Hsu, C. et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. _J. Clin. Oncol._ **35**, 4050–4056 (2017).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28837405)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitFemt7fK)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Safety%20and%20antitumor%20activity%20of%20pembrolizumab%20in%20patients%20with%20programmed%20death-ligand%201-positive%20nasopharyngeal%20carcinoma%3A%20results%20of%20the%20KEYNOTE-028%20study&journal=J.%20Clin.%20Oncol.&volume=35&pages=4050-4056&publication_year=2017&author=Hsu%2CC) 
    
10.  Ma, B. B. Y. et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742). _J. Clin. Oncol._ **36**, 1412–1418 (2018).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29584545)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941615)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtlCitrs%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Antitumor%20activity%20of%20nivolumab%20in%20recurrent%20and%20metastatic%20nasopharyngeal%20carcinoma%3A%20an%20international%2C%20multicenter%20study%20of%20the%20Mayo%20Clinic%20Phase%202%20Consortium%20%28NCI-9742%29&journal=J.%20Clin.%20Oncol.&volume=36&pages=1412-1418&publication_year=2018&author=Ma%2CBBY) 
    
11.  Fang, W. et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. _Lancet Oncol._ **19**, 1338–1350 (2018).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30213452)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhs1yltb3O)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Camrelizumab%20%28SHR-1210%29%20alone%20or%20in%20combination%20with%20gemcitabine%20plus%20cisplatin%20for%20nasopharyngeal%20carcinoma%3A%20results%20from%20two%20single-arm%2C%20phase%201%20trials&journal=Lancet%20Oncol.&volume=19&pages=1338-1350&publication_year=2018&author=Fang%2CW) 
    
12.  Wang, F. H. et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). _J. Clin. Oncol._ **39**, 704–712 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33492986)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078488)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XjtVOrtr0%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Efficacy%2C%20safety%2C%20and%20correlative%20biomarkers%20of%20toripalimab%20in%20previously%20treated%20recurrent%20or%20metastatic%20nasopharyngeal%20carcinoma%3A%20a%20phase%20II%20clinical%20trial%20%28POLARIS-02%29&journal=J.%20Clin.%20Oncol.&volume=39&pages=704-712&publication_year=2021&author=Wang%2CFH) 
    
13.  McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. _Cell_ **171**, 1259–1271.e11 (2017).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29107330)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720478)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslehs7nL)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Allele-specific%20HLA%20loss%20and%20immune%20escape%20in%20lung%20cancer%20evolution&journal=Cell&volume=171&pages=1259-1271.e11&publication_year=2017&author=McGranahan%2CN) 
    
14.  House, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. _Clin. Cancer Res._ **26**, 487–504 (2020).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31636098)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslKnt7rK)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Macrophage-derived%20CXCL9%20and%20CXCL10%20are%20required%20for%20antitumor%20immune%20responses%20following%20immune%20checkpoint%20blockade&journal=Clin.%20Cancer%20Res.&volume=26&pages=487-504&publication_year=2020&author=House%2CIG) 
    
15.  Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. _Nature_ **567**, 479–485 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30894752)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954100)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXmslKntrY%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Neoantigen-directed%20immune%20escape%20in%20lung%20cancer%20evolution&journal=Nature&volume=567&pages=479-485&publication_year=2019&author=Rosenthal%2CR) 
    
16.  Sun, Y. et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. _Cell_ **184**, 404–421.e16 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33357445)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXis12hsb3F)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Single-cell%20landscape%20of%20the%20ecosystem%20in%20early-relapse%20hepatocellular%20carcinoma&journal=Cell&volume=184&pages=404-421.e16&publication_year=2021&author=Sun%2CY) 
    
17.  Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. _Cell_ **174**, 1293–1308.e36 (2018).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29961579)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348010)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXht1Cis7vN)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Single-cell%20map%20of%20diverse%20immune%20phenotypes%20in%20the%20breast%20tumor%20microenvironment&journal=Cell&volume=174&pages=1293-1308.e36&publication_year=2018&author=Azizi%2CE) 
    
18.  Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor microenvironment. _Nat. Med._ **24**, 1277–1289 (2018).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29988129)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtlWjs7vM)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Phenotype%20molding%20of%20stromal%20cells%20in%20the%20lung%20tumor%20microenvironment&journal=Nat.%20Med.&volume=24&pages=1277-1289&publication_year=2018&author=Lambrechts%2CD) 
    
19.  Marx, V. Method of the year: spatially resolved transcriptomics. _Nat. Methods_ **18**, 9–14 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33408395)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXnsFWhsA%3D%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Method%20of%20the%20year%3A%20spatially%20resolved%20transcriptomics&journal=Nat.%20Methods&volume=18&pages=9-14&publication_year=2021&author=Marx%2CV) 
    
20.  Chen, Y. P. et al. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. _Cell Res._ **30**, 1024–1042 (2020).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32686767)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784929)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVSrt7zP)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Single-cell%20transcriptomics%20reveals%20regulators%20underlying%20immune%20cell%20diversity%20and%20immune%20subtypes%20associated%20with%20prognosis%20in%20nasopharyngeal%20carcinoma&journal=Cell%20Res.&volume=30&pages=1024-1042&publication_year=2020&author=Chen%2CYP) 
    
21.  Jin, S. et al. Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. _Cell Res._ **30**, 950–965 (2020).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32901110)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784966)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvVWjsL3I)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Single-cell%20transcriptomic%20analysis%20defines%20the%20interplay%20between%20tumor%20cells%2C%20viral%20infection%2C%20and%20the%20microenvironment%20in%20nasopharyngeal%20carcinoma&journal=Cell%20Res.&volume=30&pages=950-965&publication_year=2020&author=Jin%2CS) 
    
22.  Liu, Y. et al. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. _Nat. Commun._ **12**, 741 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33531485)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854640)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXjtlejsbo%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Tumour%20heterogeneity%20and%20intercellular%20networks%20of%20nasopharyngeal%20carcinoma%20at%20single%20cell%20resolution&journal=Nat.%20Commun.&volume=12&publication_year=2021&author=Liu%2CY) 
    
23.  Gong, L. et al. Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. _Nat. Commun._ **12**, 1540 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33750785)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943808)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXmsVCkt70%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Comprehensive%20single-cell%20sequencing%20reveals%20the%20stromal%20dynamics%20and%20tumor-specific%20characteristics%20in%20the%20microenvironment%20of%20nasopharyngeal%20carcinoma&journal=Nat.%20Commun.&volume=12&publication_year=2021&author=Gong%2CL) 
    
24.  You, R. et al. Clonal mutations activate the NF-κB pathway to promote recurrence of nasopharyngeal carcinoma. _Cancer Res._ **79**, 5930–5943 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31484669)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXjslCqs7w%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Clonal%20mutations%20activate%20the%20NF-%CE%BAB%20pathway%20to%20promote%20recurrence%20of%20nasopharyngeal%20carcinoma&journal=Cancer%20Res.&volume=79&pages=5930-5943&publication_year=2019&author=You%2CR) 
    
25.  Ding, X. et al. Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II study. _J. Clin. Oncol._ **41**, 2571–2583 (2023).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36735896)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414735)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXhtVeitbbP)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Camrelizumab%20plus%20apatinib%20in%20patients%20with%20recurrent%20or%20metastatic%20nasopharyngeal%20carcinoma%3A%20an%20open-label%2C%20single-arm%2C%20phase%20II%20study&journal=J.%20Clin.%20Oncol.&volume=41&pages=2571-2583&publication_year=2023&author=Ding%2CX) 
    
26.  Zhang, L. et al. Genomic analysis of nasopharyngeal carcinoma reveals TME-based subtypes. _Mol. Cancer Res._ **15**, 1722–1732 (2017).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28851814)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvFWht73J)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Genomic%20analysis%20of%20nasopharyngeal%20carcinoma%20reveals%20TME-based%20subtypes&journal=Mol.%20Cancer%20Res.&volume=15&pages=1722-1732&publication_year=2017&author=Zhang%2CL) 
    
27.  Palla, G. et al. Squidpy: a scalable framework for spatial omics analysis. _Nat. Methods_ **19**, 171–178 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35102346)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828470)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XisFKrt7Y%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Squidpy%3A%20a%20scalable%20framework%20for%20spatial%20omics%20analysis&journal=Nat.%20Methods&volume=19&pages=171-178&publication_year=2022&author=Palla%2CG) 
    
28.  Chen, Y. et al. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. _Cancer Cell_ **40**, 818–834.e9 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35868307)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831277)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhvV2it7vL)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Oncogenic%20collagen%20I%20homotrimers%20from%20cancer%20cells%20bind%20to%20%CE%B13%CE%B21%20integrin%20and%20impact%20tumor%20microbiome%20and%20immunity%20to%20promote%20pancreatic%20cancer&journal=Cancer%20Cell&volume=40&pages=818-834.e9&publication_year=2022&author=Chen%2CY) 
    
29.  Kobayashi, H. et al. The origin and contribution of cancer-associated fibroblasts in colorectal carcinogenesis. _Gastroenterology_ **162**, 890–906 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34883119)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhtlWgtLjL)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20origin%20and%20contribution%20of%20cancer-associated%20fibroblasts%20in%20colorectal%20carcinogenesis&journal=Gastroenterology&volume=162&pages=890-906&publication_year=2022&author=Kobayashi%2CH) 
    
30.  Egeblad, M., Rasch, M. G. & Weaver, V. M. Dynamic interplay between the collagen scaffold and tumor evolution. _Curr. Opin. Cell Biol._ **22**, 697–706 (2010).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20822891)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948601)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXht1Cls73E)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dynamic%20interplay%20between%20the%20collagen%20scaffold%20and%20tumor%20evolution&journal=Curr.%20Opin.%20Cell%20Biol.&volume=22&pages=697-706&publication_year=2010&author=Egeblad%2CM&author=Rasch%2CMG&author=Weaver%2CVM) 
    
31.  Shin, H. J., Gil, M. & Lee, I. S. Association of elevated expression levels of COL4A1 in stromal cells with an immunosuppressive tumor microenvironment in low-grade glioma, pancreatic adenocarcinoma, skin cutaneous melanoma, and stomach adenocarcinoma. _J. Pers. Med._ **12**, 534 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35455650)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029283)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Association%20of%20elevated%20expression%20levels%20of%20COL4A1%20in%20stromal%20cells%20with%20an%20immunosuppressive%20tumor%20microenvironment%20in%20low-grade%20glioma%2C%20pancreatic%20adenocarcinoma%2C%20skin%20cutaneous%20melanoma%2C%20and%20stomach%20adenocarcinoma&journal=J.%20Pers.%20Med.&volume=12&publication_year=2022&author=Shin%2CHJ&author=Gil%2CM&author=Lee%2CIS) 
    
32.  Cao, J. et al. The single-cell transcriptional landscape of mammalian organogenesis. _Nature_ **566**, 496–502 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30787437)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434952)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXnslOmtr4%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20single-cell%20transcriptional%20landscape%20of%20mammalian%20organogenesis&journal=Nature&volume=566&pages=496-502&publication_year=2019&author=Cao%2CJ) 
    
33.  Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. _Nature_ **577**, 561–565 (2020).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31942071)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXis1Sitr8%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Tertiary%20lymphoid%20structures%20improve%20immunotherapy%20and%20survival%20in%20melanoma&journal=Nature&volume=577&pages=561-565&publication_year=2020&author=Cabrita%2CR) 
    
34.  Ladanyi, A. et al. Prognostic impact of B-cell density in cutaneous melanoma. _Cancer Immunol. Immunother._ **60**, 1729–1738 (2011).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21779876)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11028465)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsFantrrL)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prognostic%20impact%20of%20B-cell%20density%20in%20cutaneous%20melanoma&journal=Cancer%20Immunol.%20Immunother.&volume=60&pages=1729-1738&publication_year=2011&author=Ladanyi%2CA) 
    
35.  Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: Potential for patient selection for immunotherapy? _Sci. Rep._ **2**, 765 (2012).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23097687)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479449)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=12-Chemokine%20gene%20signature%20identifies%20lymph%20node-like%20structures%20in%20melanoma%3A%20Potential%20for%20patient%20selection%20for%20immunotherapy%3F&journal=Sci.%20Rep.&volume=2&publication_year=2012&author=Messina%2CJL) 
    
36.  Cipponi, A. et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. _Cancer Res._ **72**, 3997–4007 (2012).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22850419)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhtF2rtrrO)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Neogenesis%20of%20lymphoid%20structures%20and%20antibody%20responses%20occur%20in%20human%20melanoma%20metastases&journal=Cancer%20Res.&volume=72&pages=3997-4007&publication_year=2012&author=Cipponi%2CA) 
    
37.  Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. _Nat. Rev. Cancer_ **19**, 307–325 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31092904)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVSqsLzP)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Tertiary%20lymphoid%20structures%20in%20the%20era%20of%20cancer%20immunotherapy&journal=Nat.%20Rev.%20Cancer&volume=19&pages=307-325&publication_year=2019&author=Sautes-Fridman%2CC&author=Petitprez%2CF&author=Calderaro%2CJ&author=Fridman%2CWH) 
    
38.  Yu, Y. et al. Cancer-associated fibroblasts induce epithelial–mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. _Br. J. Cancer_ **110**, 724–732 (2014).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24335925)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhvFCqtLjL)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cancer-associated%20fibroblasts%20induce%20epithelial%E2%80%93mesenchymal%20transition%20of%20breast%20cancer%20cells%20through%20paracrine%20TGF-%CE%B2%20signalling&journal=Br.%20J.%20Cancer&volume=110&pages=724-732&publication_year=2014&author=Yu%2CY) 
    
39.  Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. _Nature_ **487**, 500–504 (2012).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22763439)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711467)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhtFWjtL3J)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Tumour%20micro-environment%20elicits%20innate%20resistance%20to%20RAF%20inhibitors%20through%20HGF%20secretion&journal=Nature&volume=487&pages=500-504&publication_year=2012&author=Straussman%2CR) 
    
40.  Yang, H. et al. Multi-scale integrative analyses identify THBS2+ cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma. _Theranostics_ **12**, 3104–3130 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35547750)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065207)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhsFKrsL3F)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Multi-scale%20integrative%20analyses%20identify%20THBS2%2B%20cancer-associated%20fibroblasts%20as%20a%20key%20orchestrator%20promoting%20aggressiveness%20in%20early-stage%20lung%20adenocarcinoma&journal=Theranostics&volume=12&pages=3104-3130&publication_year=2022&author=Yang%2CH) 
    
41.  Ma, Z. et al. Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. _Cancer Cell_ **40**, 1550–1565.e7 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36459995)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XjtVCjs7nO)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Interferon-dependent%20SLC14A1%2B%20cancer-associated%20fibroblasts%20promote%20cancer%20stemness%20via%20WNT5A%20in%20bladder%20cancer&journal=Cancer%20Cell&volume=40&pages=1550-1565.e7&publication_year=2022&author=Ma%2CZ) 
    
42.  Tang, L. L. et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. _Cancer Commun. (Lond.)_ **41**, 1195–1227 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34699681)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20Chinese%20Society%20of%20Clinical%20Oncology%20%28CSCO%29%20clinical%20guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20nasopharyngeal%20carcinoma&journal=Cancer%20Commun.%20%28Lond.%29&volume=41&pages=1195-1227&publication_year=2021&author=Tang%2CLL) 
    
43.  Melnikova, V. O. & Bar-Eli, M. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. _Pigment Cell Res._ **19**, 395–405 (2006).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16965268)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28Xht1SrurfI)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Bioimmunotherapy%20for%20melanoma%20using%20fully%20human%20antibodies%20targeting%20MCAM%2FMUC18%20and%20IL-8&journal=Pigment%20Cell%20Res.&volume=19&pages=395-405&publication_year=2006&author=Melnikova%2CVO&author=Bar-Eli%2CM) 
    
44.  Giannelli, G. et al. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. _PLoS ONE_ **15**, e0222259 (2020).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32210440)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094874)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXosFCrtrg%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Biomarkers%20and%20overall%20survival%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20treated%20with%20TGF-%CE%B2RI%20inhibitor%20galunisertib&journal=PLoS%20ONE&volume=15&publication_year=2020&author=Giannelli%2CG) 
    
45.  Wick, A. et al. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. _Invest. New Drugs_ **38**, 1570–1579 (2020).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32140889)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497674)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXlslyrsbk%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Phase%201b%2F2a%20study%20of%20galunisertib%2C%20a%20small%20molecule%20inhibitor%20of%20transforming%20growth%20factor-beta%20receptor%20I%2C%20in%20combination%20with%20standard%20temozolomide-based%20radiochemotherapy%20in%20patients%20with%20newly%20diagnosed%20malignant%20glioma&journal=Invest.%20New%20Drugs&volume=38&pages=1570-1579&publication_year=2020&author=Wick%2CA) 
    
46.  Melisi, D. et al. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. _Cancer Chemother. Pharmacol._ **83**, 975–991 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30887178)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtFWntbrO)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=TGF%CE%B2%20receptor%20inhibitor%20galunisertib%20is%20linked%20to%20inflammation-%20and%20remodeling-related%20proteins%20in%20patients%20with%20pancreatic%20cancer&journal=Cancer%20Chemother.%20Pharmacol.&volume=83&pages=975-991&publication_year=2019&author=Melisi%2CD) 
    
47.  Yamazaki, T. et al. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. _Lancet Oncol._ **23**, 1189–1200 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35952709)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XisVaht7%2FL)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Galunisertib%20plus%20neoadjuvant%20chemoradiotherapy%20in%20patients%20with%20locally%20advanced%20rectal%20cancer%3A%20a%20single-arm%2C%20phase%202%20trial&journal=Lancet%20Oncol.&volume=23&pages=1189-1200&publication_year=2022&author=Yamazaki%2CT) 
    
48.  De, P. et al. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. _Cancer Chemother. Pharmacol._ **71**, 867–881 (2013).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23355037)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXkvF2nurc%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=An%20integrin-targeted%2C%20pan-isoform%2C%20phosphoinositide-3%20kinase%20inhibitor%2C%20SF1126%2C%20has%20activity%20against%20multiple%20myeloma%20in%20vivo&journal=Cancer%20Chemother.%20Pharmacol.&volume=71&pages=867-881&publication_year=2013&author=De%2CP) 
    
49.  Chien, A. J. et al. MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and/or hormone receptor-negative breast cancers in the I-SPY 2 trial. _J. Clin. Oncol._ **38**, 1059–1069 (2020).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32031889)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106976)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvVSjsb7I)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=MK-2206%20and%20standard%20neoadjuvant%20chemotherapy%20improves%20response%20in%20patients%20with%20human%20epidermal%20growth%20factor%20receptor%202-positive%20and%2For%20hormone%20receptor-negative%20breast%20cancers%20in%20the%20I-SPY%202%20trial&journal=J.%20Clin.%20Oncol.&volume=38&pages=1059-1069&publication_year=2020&author=Chien%2CAJ) 
    
50.  Badalamente, M. A., Hurst, L. C. & Hentz, V. R. Collagen as a clinical target: nonoperative treatment of Dupuytren’s disease. _J. Hand. Surg. Am._ **27**, 788–798 (2002).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12239666)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Collagen%20as%20a%20clinical%20target%3A%20nonoperative%20treatment%20of%20Dupuytren%E2%80%99s%20disease&journal=J.%20Hand.%20Surg.%20Am.&volume=27&pages=788-798&publication_year=2002&author=Badalamente%2CMA&author=Hurst%2CLC&author=Hentz%2CVR) 
    
51.  Islam, M. S. et al. Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids. _Clin. Transl. Med._ **11**, e475 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34323413)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255059)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhvVygt7vF)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Extracellular%20matrix%20and%20Hippo%20signaling%20as%20therapeutic%20targets%20of%20antifibrotic%20compounds%20for%20uterine%20fibroids&journal=Clin.%20Transl.%20Med.&volume=11&publication_year=2021&author=Islam%2CMS) 
    
52.  Xu, J. Y., Wei, X. L., Wang, Y. Q. & Wang, F. H. Current status and advances of immunotherapy in nasopharyngeal carcinoma. _Ther. Adv. Med. Oncol._ **14**, 17588359221096214 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35547095)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083041)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXktFekuw%3D%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Current%20status%20and%20advances%20of%20immunotherapy%20in%20nasopharyngeal%20carcinoma&journal=Ther.%20Adv.%20Med.%20Oncol.&volume=14&publication_year=2022&author=Xu%2CJY&author=Wei%2CXL&author=Wang%2CYQ&author=Wang%2CFH) 
    
53.  Zemek, R. M. et al. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. _Sci. Transl. Med._ **11**, eaav7816 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31316010)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sensitization%20to%20immune%20checkpoint%20blockade%20through%20activation%20of%20a%20STAT1%2FNK%20axis%20in%20the%20tumor%20microenvironment&journal=Sci.%20Transl.%20Med.&volume=11&publication_year=2019&author=Zemek%2CRM) 
    
54.  Parry, E. M. et al. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. _Cancer Cell_ **41**, 1803–1816.e8 (2023).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37738974)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618915)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXhvFKktLfE)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=ZNF683%20marks%20a%20CD8%2B%20T%E2%80%89cell%20population%20associated%20with%20anti-tumor%20immunity%20following%20anti-PD-1%20therapy%20for%20Richter%20syndrome&journal=Cancer%20Cell&volume=41&pages=1803-1816.e8&publication_year=2023&author=Parry%2CEM) 
    
55.  Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. _Proc. Natl Acad. Sci. USA_ **109**, 6662–6667 (2012).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22451913)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340046)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XmslCns7Y%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20CD47-signal%20regulatory%20protein%20alpha%20%28SIRPa%29%20interaction%20is%20a%20therapeutic%20target%20for%20human%20solid%20tumors&journal=Proc.%20Natl%20Acad.%20Sci.%20USA&volume=109&pages=6662-6667&publication_year=2012&author=Willingham%2CSB) 
    
56.  Lakhani, N. J. et al. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. _Lancet Oncol._ **22**, 1740–1751 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34793719)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XmvVKhsr0%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Evorpacept%20alone%20and%20in%20combination%20with%20pembrolizumab%20or%20trastuzumab%20in%20patients%20with%20advanced%20solid%20tumours%20%28ASPEN-01%29%3A%20a%20first-in-human%2C%20open-label%2C%20multicentre%2C%20phase%201%20dose-escalation%20and%20dose-expansion%20study&journal=Lancet%20Oncol.&volume=22&pages=1740-1751&publication_year=2021&author=Lakhani%2CNJ) 
    
57.  Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. _N. Engl. J. Med._ **379**, 1711–1721 (2018).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30380386)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058634)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitFOmtLzF)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=CD47%20blockade%20by%20Hu5F9-G4%20and%20rituximab%20in%20non-Hodgkin%E2%80%99s%20lymphoma&journal=N.%20Engl.%20J.%20Med.&volume=379&pages=1711-1721&publication_year=2018&author=Advani%2CR) 
    
58.  Peluso, M. O. et al. The fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a. _J. Immunother. Cancer_ **8**, e000413 (2020).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32345627)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213910)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20fully%20human%20anti-CD47%20antibody%20SRF231%20exerts%20dual-mechanism%20antitumor%20activity%20via%20engagement%20of%20the%20activating%20receptor%20CD32a&journal=J.%20Immunother.%20Cancer&volume=8&publication_year=2020&author=Peluso%2CMO) 
    
59.  Ansell, S. M. et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. _Clin. Cancer Res._ **27**, 2190–2199 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33451977)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtl2rsb%2FM)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Phase%20I%20study%20of%20the%20CD47%20blocker%20TTI-621%20in%20patients%20with%20relapsed%20or%20refractory%20hematologic%20malignancies&journal=Clin.%20Cancer%20Res.&volume=27&pages=2190-2199&publication_year=2021&author=Ansell%2CSM) 
    
60.  Dodagatta-Marri, E. et al. Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy. _Cell Rep._ **36**, 109309 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34233193)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321414)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsFamsLzN)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Integrin%20%CE%B1v%CE%B28%20on%20T%E2%80%89cells%20suppresses%20anti-tumor%20immunity%20in%20multiple%20models%20and%20is%20a%20promising%20target%20for%20tumor%20immunotherapy&journal=Cell%20Rep.&volume=36&publication_year=2021&author=Dodagatta-Marri%2CE) 
    
61.  Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. _Genome Biol._ **19**, 15 (2018).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29409532)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802054)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=SCANPY%3A%20large-scale%20single-cell%20gene%20expression%20data%20analysis&journal=Genome%20Biol.&volume=19&publication_year=2018&author=Wolf%2CFA&author=Angerer%2CP&author=Theis%2CFJ) 
    
62.  Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. _Cell Syst._ **8**, 281–291.e9 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30954476)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625319)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXosVyhtbw%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Scrublet%3A%20computational%20identification%20of%20cell%20doublets%20in%20single-cell%20transcriptomic%20data&journal=Cell%20Syst.&volume=8&pages=281-291.e9&publication_year=2019&author=Wolock%2CSL&author=Lopez%2CR&author=Klein%2CAM) 
    
63.  Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected communities. _Sci. Rep._ **9**, 5233 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30914743)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435756)  [CAS](https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BB3cbosVGisQ%3D%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=From%20Louvain%20to%20Leiden%3A%20guaranteeing%20well-connected%20communities&journal=Sci.%20Rep.&volume=9&publication_year=2019&author=Traag%2CVA&author=Waltman%2CL&author=Eck%2CNJ) 
    
64.  Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. _Nat. Biotechnol._ **37**, 38–44 (2019).
    
    [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitl2isbrN)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Dimensionality%20reduction%20for%20visualizing%20single-cell%20data%20using%20UMAP&journal=Nat.%20Biotechnol.&volume=37&pages=38-44&publication_year=2019&author=Becht%2CE) 
    
65.  Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. _Nat. Methods_ **16**, 1289–1296 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31740819)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884693)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFOqsr7N)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Fast%2C%20sensitive%20and%20accurate%20integration%20of%20single-cell%20data%20with%20Harmony&journal=Nat.%20Methods&volume=16&pages=1289-1296&publication_year=2019&author=Korsunsky%2CI) 
    
66.  Tran, H. T. N. et al. A benchmark of batch-effect correction methods for single-cell RNA sequencing data. _Genome Biol._ **21**, 12 (2020).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31948481)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964114)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXkvVWlt7g%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20benchmark%20of%20batch-effect%20correction%20methods%20for%20single-cell%20RNA%20sequencing%20data&journal=Genome%20Biol.&volume=21&publication_year=2020&author=Tran%2CHTN) 
    
67.  Peng, J. et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. _Cell Res._ **29**, 725–738 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31273297)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796938)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsFyqsbvL)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Single-cell%20RNA-seq%20highlights%20intra-tumoral%20heterogeneity%20and%20malignant%20progression%20in%20pancreatic%20ductal%20adenocarcinoma&journal=Cell%20Res.&volume=29&pages=725-738&publication_year=2019&author=Peng%2CJ) 
    
68.  Gulati, G. S. et al. Single-cell transcriptional diversity is a hallmark of developmental potential. _Science_ **367**, 405–411 (2020).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31974247)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694873)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvVaksb4%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Single-cell%20transcriptional%20diversity%20is%20a%20hallmark%20of%20developmental%20potential&journal=Science&volume=367&pages=405-411&publication_year=2020&author=Gulati%2CGS) 
    
69.  Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. _OMICS_ **16**, 284–287 (2012).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22455463)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339379)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XmsFarsLw%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=clusterProfiler%3A%20an%20R%20package%20for%20comparing%20biological%20themes%20among%20gene%20clusters&journal=OMICS&volume=16&pages=284-287&publication_year=2012&author=Yu%2CG&author=Wang%2CLG&author=Han%2CY&author=He%2CQY) 
    
70.  Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. _Nat. Commun._ **10**, 1523 (2019).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30944313)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447622)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Metascape%20provides%20a%20biologist-oriented%20resource%20for%20the%20analysis%20of%20systems-level%20datasets&journal=Nat.%20Commun.&volume=10&publication_year=2019&author=Zhou%2CY) 
    
71.  Szklarczyk, D. et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. _Nucleic Acids Res._ **49**, D605–D612 (2021).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33237311)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXntlejtb0%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20STRING%20database%20in%202021%3A%20customizable%20protein%E2%80%93protein%20networks%2C%20and%20functional%20characterization%20of%20user-uploaded%20gene%2Fmeasurement%20sets&journal=Nucleic%20Acids%20Res.&volume=49&pages=D605-D612&publication_year=2021&author=Szklarczyk%2CD) 
    
72.  Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. _Genome Res._ **13**, 2498–2504 (2003).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14597658)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC403769)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD3sXovFWrtr4%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cytoscape%3A%20a%20software%20environment%20for%20integrated%20models%20of%20biomolecular%20interaction%20networks&journal=Genome%20Res.&volume=13&pages=2498-2504&publication_year=2003&author=Shannon%2CP) 
    
73.  Dimitrov, D. et al. Comparison of methods and resources for cell–cell communication inference from single-cell RNA-seq data. _Nat. Commun._ **13**, 3224 (2022).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35680885)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184522)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Comparison%20of%20methods%20and%20resources%20for%20cell%E2%80%93cell%20communication%20inference%20from%20single-cell%20RNA-seq%20data&journal=Nat.%20Commun.&volume=13&publication_year=2022&author=Dimitrov%2CD) 
    
74.  Kolde, R., Laur, S., Adler, P. & Vilo, J. Robust rank aggregation for gene list integration and meta-analysis. _Bioinformatics_ **28**, 573–580 (2012).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22247279)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278763)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xis1emsL4%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Robust%20rank%20aggregation%20for%20gene%20list%20integration%20and%20meta-analysis&journal=Bioinformatics&volume=28&pages=573-580&publication_year=2012&author=Kolde%2CR&author=Laur%2CS&author=Adler%2CP&author=Vilo%2CJ) 
    
75.  Schubert, M. et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. _Nat. Commun._ **9**, 20 (2018).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29295995)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750219)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Perturbation-response%20genes%20reveal%20signaling%20footprints%20in%20cancer%20gene%20expression&journal=Nat.%20Commun.&volume=9&publication_year=2018&author=Schubert%2CM) 
    
76.  Badia, I. M. P. et al. decoupleR: ensemble of computational methods to infer biological activities from omics data. _Bioinform Adv_ **2**, vbac016 (2022).
    
    [Google Scholar](http://scholar.google.com/scholar_lookup?&title=decoupleR%3A%20ensemble%20of%20computational%20methods%20to%20infer%20biological%20activities%20from%20omics%20data&journal=Bioinform%20Adv&volume=2&publication_year=2022&author=Badia%2CIMP) 
    
77.  Ru, B., Huang, J., Zhang, Y., Aldape, K. & Jiang, P. Estimation of cell lineages in tumors from spatial transcriptomics data. _Nat. Commun._ **14**, 568 (2023).
    
    [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36732531)  [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895078)  [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXivFamurk%3D)  [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Estimation%20of%20cell%20lineages%20in%20tumors%20from%20spatial%20transcriptomics%20data&journal=Nat.%20Commun.&volume=14&publication_year=2023&author=Ru%2CB&author=Huang%2CJ&author=Zhang%2CY&author=Aldape%2CK&author=Jiang%2CP) 
    
78.  You, R. et al. Custom code for study: single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma. _Zenodo_ [https://doi.org/10.5281/zenodo.15104454](https://doi.org/10.5281/zenodo.15104454) (2025).
    

[Download references](https://citation-needed.springer.com/v2/references/10.1038/s41588-025-02253-8?format=refman&flavour=references)

Acknowledgements
----------------

Funding was provided by the National Natural Science Foundation of China (no. 82230034 to M.Y.C., 82373407 to R.Y., 82471134 to Y.P.L. and 82203231 to T.L.X.), the Guangzhou Science and Technology Plan Project (no. 202103010001 to M.Y.C.), the National Key Research and Development Program of China (no. 2021YFA1302500 to S.H.Z.), Guangzhou Science and Technology Plan Projects (no. 2023A04J1760 to T.L.X.) and Jiangxi Provincial Natural Science Foundation of China (no. 20212BDH80023 to M.Y.C.).

Author information
------------------

Author notes

1.  These authors contributed equally: Rui You, Qunlun Shen, Chao Lin, Kangning Dong, Xiao Liu, Hanshi Xu.
    
2.  These authors jointly supervised this work: Mingyuan Chen, Shihua Zhang, Tianliang Xia, Youping Liu, Rui You.
    

### Authors and Affiliations

1.  Nasopharyngeal Cancer Center, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, The People’s Republic of China
    
    Rui You, Xiao Liu, Xiaoyi Song, Chunliu Huang, Youping Liu & Mingyuan Chen
    
2.  Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, The People’s Republic of China
    
    Rui You, Chao Lin, Hanshi Xu, Yulong Xie, Ruoqi Xie, Huifeng Li, Xiong Zou, Peiyu Huang, Yijun Hua & Mingyuan Chen
    
3.  State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, The People’s Republic of China
    
    Rui You, Chao Lin, Hanshi Xu, Wanming Hu, Yulong Xie, Ruoqi Xie, Jinhui Wu, Tao Yu, Huifeng Li, Zining Wang, Keming Chen, Xiong Zou, Peiyu Huang, Yijun Hua, Tianliang Xia & Mingyuan Chen
    
4.  State Key Laboratory of Mathematical Sciences, Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, The People’s Republic of China
    
    Qunlun Shen & Shihua Zhang
    
5.  School of Mathematical Sciences, University of Chinese Academy of Sciences, Beijing, The People’s Republic of China
    
    Qunlun Shen & Shihua Zhang
    
6.  Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, The People’s Republic of China
    
    Chao Lin
    
7.  School of Mathematics, Renmin University of China, Beijing, The People’s Republic of China
    
    Kangning Dong
    
8.  Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, The People’s Republic of China
    
    Wanming Hu & Keming Chen
    
9.  Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Hangzhou, The People’s Republic of China
    
    Shihua Zhang
    

Authors

1.  Rui You
    
    [View author publications](https://www.nature.com/search?author=Rui%20You)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Rui%20You) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Rui%20You%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
2.  Qunlun Shen
    
    [View author publications](https://www.nature.com/search?author=Qunlun%20Shen)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Qunlun%20Shen) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Qunlun%20Shen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
3.  Chao Lin
    
    [View author publications](https://www.nature.com/search?author=Chao%20Lin)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chao%20Lin) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chao%20Lin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
4.  Kangning Dong
    
    [View author publications](https://www.nature.com/search?author=Kangning%20Dong)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kangning%20Dong) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kangning%20Dong%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
5.  Xiao Liu
    
    [View author publications](https://www.nature.com/search?author=Xiao%20Liu)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiao%20Liu) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiao%20Liu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
6.  Hanshi Xu
    
    [View author publications](https://www.nature.com/search?author=Hanshi%20Xu)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hanshi%20Xu) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hanshi%20Xu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
7.  Wanming Hu
    
    [View author publications](https://www.nature.com/search?author=Wanming%20Hu)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wanming%20Hu) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wanming%20Hu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
8.  Yulong Xie
    
    [View author publications](https://www.nature.com/search?author=Yulong%20Xie)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yulong%20Xie) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yulong%20Xie%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
9.  Ruoqi Xie
    
    [View author publications](https://www.nature.com/search?author=Ruoqi%20Xie)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ruoqi%20Xie) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ruoqi%20Xie%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
10.  Xiaoyi Song
    
    [View author publications](https://www.nature.com/search?author=Xiaoyi%20Song)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiaoyi%20Song) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiaoyi%20Song%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
11.  Chunliu Huang
    
    [View author publications](https://www.nature.com/search?author=Chunliu%20Huang)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chunliu%20Huang) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chunliu%20Huang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
12.  Jinhui Wu
    
    [View author publications](https://www.nature.com/search?author=Jinhui%20Wu)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jinhui%20Wu) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jinhui%20Wu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
13.  Tao Yu
    
    [View author publications](https://www.nature.com/search?author=Tao%20Yu)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tao%20Yu) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tao%20Yu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
14.  Huifeng Li
    
    [View author publications](https://www.nature.com/search?author=Huifeng%20Li)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Huifeng%20Li) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Huifeng%20Li%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
15.  Zining Wang
    
    [View author publications](https://www.nature.com/search?author=Zining%20Wang)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Zining%20Wang) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Zining%20Wang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
16.  Keming Chen
    
    [View author publications](https://www.nature.com/search?author=Keming%20Chen)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Keming%20Chen) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Keming%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
17.  Xiong Zou
    
    [View author publications](https://www.nature.com/search?author=Xiong%20Zou)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiong%20Zou) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiong%20Zou%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
18.  Peiyu Huang
    
    [View author publications](https://www.nature.com/search?author=Peiyu%20Huang)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Peiyu%20Huang) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Peiyu%20Huang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
19.  Yijun Hua
    
    [View author publications](https://www.nature.com/search?author=Yijun%20Hua)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yijun%20Hua) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yijun%20Hua%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
20.  Youping Liu
    
    [View author publications](https://www.nature.com/search?author=Youping%20Liu)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Youping%20Liu) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Youping%20Liu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
21.  Tianliang Xia
    
    [View author publications](https://www.nature.com/search?author=Tianliang%20Xia)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tianliang%20Xia) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tianliang%20Xia%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
22.  Shihua Zhang
    
    [View author publications](https://www.nature.com/search?author=Shihua%20Zhang)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shihua%20Zhang) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shihua%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    
23.  Mingyuan Chen
    
    [View author publications](https://www.nature.com/search?author=Mingyuan%20Chen)
    
    Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mingyuan%20Chen) [Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mingyuan%20Chen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)
    

### Contributions

M.Y.C., S.H.Z., T.L.X., Y.P.L. and R.Y. conceived and designed the project and the strategy. R.Y., X.Z., P.Y.H., Y.J.H., Y.P.L. and M.Y.C. collected and created the samples. S.H.Z., Q.L.S., K.N.D., H.S.X., X.Y.S. and R.Q.X. designed and performed the computation and statistical analysis. C.L., X.L., C.L.H., Y.L.X., J.H.W., T.Y., H.F.L., Z.N.W., K.M.C., T.L.X. and R.Y. designed and performed the experiments. W.M.H. conducted the pathological evaluation. M.Y.C., S.H.Z., T.L.X., Y.P.L. and R.Y. supervised the study. All authors wrote, reviewed and edited the manuscript.

### Corresponding authors

Correspondence to [Rui You](mailto:your5@mail.sysu.edu.cn), [Youping Liu](mailto:liuyp78@mail.sysu.edu.cn), [Tianliang Xia](mailto:xiatl@sysucc.org.cn), [Shihua Zhang](mailto:zsh@amss.ac.cn) or [Mingyuan Chen](mailto:chmingy@mail.sysu.edu.cn).

Ethics declarations
-------------------

### Competing interests

The authors declare no competing interests.

Peer review
-----------

### Peer review information

_Nature Genetics_ thanks Wei Dai and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. [Peer reviewer reports](https://www.nature.com/articles/s41588-025-02253-8#MOESM3) are available.

Additional information
----------------------

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data
-------------

### [Extended Data Fig. 1 ScRNA-seq and spatial profiling of the TME of pNPC and rNPC, related to Fig.](https://www.nature.com/articles/s41588-025-02253-8/figures/9) [1](https://www.nature.com/articles/s41588-025-02253-8#Fig1).

(**a**) Histogram indicating the total number of detected genes (left panel) and the number of read counts (right panel). (**b**) Violin plot showing the expression levels of 8 known housekeeping genes in all cells. (**c**) UMAP plot for cells before integration, cells are colored according to the origin of patients (left panel), disease states (middle panel), and cell types (right panel). (**d**) Boxplot showing the acceptance rate calculated by kBET in uncorrected single cells and harmony-corrected ones. (**e**) Heatmap of the copy number variants (CNV) analysis, inferred from the scRNA-seq data. Each row indicates a single cell, NK and B cells were used as references. (**f**) Violin plot showing the CNV scores of inferred malignant cells and normal epithelial cells. Two-sided Wilcoxon rank-sum test. (**g**) UMAP plot showing the expression levels of marker genes, defined for major cell types. (**h**) Histogram indicating the ratio of cells in PT (blue) and RT (red) tissue samples. (**i**) Boxplot showing the number of detected genes of the indicated patients per spot across spatial data. (**j**\-**k**) Count of programs in PT (blue) and RT (red) samples in Fig. [1f](https://www.nature.com/articles/s41588-025-02253-8#Fig1).

### [Extended Data Fig. 2 Characteristics of malignant cells in PT and RT samples, related to Fig.](https://www.nature.com/articles/s41588-025-02253-8/figures/10) [2](https://www.nature.com/articles/s41588-025-02253-8#Fig2).

(**a**) Volcano plot shows differentially expressed genes (DEGs) between PT (blue) and RT (red) malignant cells, genes with top10 fold-changes are shown for each group. (**b**) Gene Set Enrichment Analysis (GSEA) and Gene Ontology of the DEGs between malignant cells from PT (blue) and RT (red) samples, based on the subontology of biological processes. (**c**) The proportion of significant interactions from fibroblasts to malignant cells compared with significant interactions from other immune cells to malignant cells inferred by LIANA. For fibroblasts, the proportion was calculated using the interaction number between fibroblasts (source) and tumor cells (target) as the numerator and the total interactions sent from fibroblasts as the denominator. For other immune cells, the proportion was calculated using the interaction number between other immune cells (source) and tumor cells (target) as the numerator and the total interactions sent from other immune cells as the denominator. Two-sided proportions z-test. (**d**) Schematic diagram illustrating the construction of radioresistant cell lines. (**e**) Representative images of the colony-forming assay of radiation-resistant (R, red) and wild type (W, blue) C666 and TW03 cell lines after being irradiated at doses of 0, 2, 4, 6, and 8 Gy. The right panel indicates the survival fractions of each cell line. Two-sided paired _t_\-test. Scale bars, 5 mm. (**f**) The Spearman correlation between mutation load and the signature scores of four cancer cell-intrinsic transcriptional programs within PT and RT. Two-sided Spearman’s correlation test. (**g**) The Spearman correlation between mutation load and the ratios of various cell populations in TME within PT and RT. Two-sided Spearman’s correlation test. (**h**) Characterization of malignant cells and fibroblasts on spatial transcriptomics data using cell-type deconvolution. Scale bars, 500 µm. (**i**) Bar chart showing the number of significant L-R interactions from immune cells to malignant cells in PT (blue) and RT (red) samples.

[Source data](https://www.nature.com/articles/s41588-025-02253-8#MOESM12)

### [Extended Data Fig. 3 MCAM+ fibroblasts were identified in rNPC and promoted the radioresistance of NPC tumor cells, related to Fig.](https://www.nature.com/articles/s41588-025-02253-8/figures/11) [3](https://www.nature.com/articles/s41588-025-02253-8#Fig3).

(**a**) Dotplot showing the normalized expression of marker genes belonging to the clusters defined in Fig. [3a](https://www.nature.com/articles/s41588-025-02253-8#Fig3). (**b**) Track plot showing the normalized expression of mCAF markers (_ACTA2_, _POSTN_) and the iCAF marker (_CFD_) in 4 CAF subclusters. Gene expression is represented by height. (**c**) Heatmap showing the normalized expression of _MCAM_ and _ACTA2_ for each cell type. (**d**) Enrichment analysis of the top 50 DEGs based on the subtypes of CAFs, calculated using Metascape. (**e**) The primary fibroblasts were cultured from PT (left) and RT (right) samples. The images were taken by a microscope. Scale bars, 400 µm. (**f**) CAFs from PT and RT tissues were isolated and detected by flow cytometry. (**g**) MTT assay of NPC cell lines co-cultured with MCAM+ or MCAM− CAFs, with PBS as control. Two-sided paired _t_\-test. (**h**) Representative immunofluorescent staining images show the expression of DAPI, Ki67, and MCAM in MCAM+ mCAFs and MCAM− CAFs. Scale bars, 50 µm. Two-sided _t_\-test. (**i**) TW03 and C666 cells were co-cultured with MCAM+ mCAFs or MCAM− CAFs, after irradiation at the doses of 10 Gy, 15 Gy, and 20 Gy. The distribution of γ-H2AX foci was visualized by immunofluorescence staining. The cell nuclei were counter-stained with DAPI (blue). Scale bars, 20 µm. (**j**) Representative images of the colony-forming assay of NPC cell lines after being co-cultured with MCAM+ mCAFs or MCAM− CAFs, followed by different irradiation dose gradients (10 Gy, 15 Gy, and 20 Gy). Scale bars, 5 mm. (**k**) C666 cells (1 × 106) were injected alone or combined with MCAM+ or MCAM− CAFs (3:1) subcutaneously into the haunch of each nude mouse (n = 6 per group). After 6-8 days, all NCG mice were treated with local radiotherapy at a dose of 2 Gy for 5 consecutive days. (**l**) Representative IHC images immunofluorescent staining images show the expression of _PANCK_, _DAPI_, _ACTA2_, and _MCAM_ in MCAM+ mCAFs and MCAM− CAFs. Scale bars, 50 µm.

[Source data](https://www.nature.com/articles/s41588-025-02253-8#MOESM13)

### [Extended Data Fig. 4 MCAM+ mCAFs promoted the radioresistance of NPC cells via the COL4-ITGA2-PI3K-AKT axis, related to Fig.](https://www.nature.com/articles/s41588-025-02253-8/figures/12) [4](https://www.nature.com/articles/s41588-025-02253-8#Fig4).

(**a**) The expression of representative markers between MCAM+ and MCAM− mCAFs cells in the single cell (log (CPM + 1)) and bulk RNA seq cohort (log (FPKM + 1)). CPM, Counts Per Million; FPKM, Fragments Per Kilobase Million. (**b**\-**c**) The percentage of apoptotic cells in the C666 cell line (**b**) and the TW03 cell line (**c**) was quantified by flow cytometry, treated with recombinant PDGFA or IGFBP7 protein, and irradiation at a dose of 10 Gy (n = 3 per group). Quantification represented by a bar plot (mean ± SD), right. Two-sided _t_\-test. (**d**) Western blotting for the expression of _COL4A1_ in MCAM+ mCAFs and COL4A1KD MCAM+ mCAFs. (**e**) ELISA for type IV collagen in the supernatant of MCAM+ CAFs and COL4A1KD MCAM+ mCAFs, ng/ml (n = 3 per group). Two-sided _t_\-test. (**f**) The correlation between the ratio of malignant cells and the expression of _ITGA2_ and _ITGA3_ based on RNA-seq data from Validation cohort 4. Two-sided Spearman’s correlation test. (**g**) Western blotting for the expression of COL4A1, COL4A2, vimentin, and α-SMA in MCAM+ mCAFs with or without knockdown _COL4A1_. (**h**) Representative images of the colony-forming assay of NPC cell lines after being treated with different concentration gradients of Collagen IV followed by irradiation (10 Gy) (n = 3 per group). Quantification represented by a bar plot (mean ± SD), right. Two-sided _t_\-test. Scale bars, 5 mm. (**i**) Representative images of _PANCK_, _ITGA2_, _ITGA3_, and collagen IV in situ IHC staining in NPC samples. Scale bars, 50 µm. (**j**) Boxplot showing the expression of _ITGA2_ (left) and _ITGA3_ (right) in wide type (W, blue) and radioresistant type (R, Red) cell lines (n = 3 per group). One-sided paired _t_\-test. (**k**) HEK293T cells were transfected with Flag-_COL4A1_, HA-_ITGA2_, or the related vector control and then subjected to immunoprecipitation and immunoblot with the designated antibodies.

[Source data](https://www.nature.com/articles/s41588-025-02253-8#MOESM14)

### [Extended Data Fig. 5 The formation of MCAM+ mCAFs was induced via TGF-β signaling, related to Fig.](https://www.nature.com/articles/s41588-025-02253-8/figures/13) [4](https://www.nature.com/articles/s41588-025-02253-8#Fig4).

(**a**\-**b**) Western blotting for key proteins of the FAK-AKT pathway in the indicated NPC cell lines, with or without collagen IV pretreatment (**a**), and with or without ITGA2 knockdown following collagen IV pretreatment (**b**). (**c**) TW03 and C666 cells were treated with or without the AKT inhibitor MK2206 in the presence of type IV collagen. After irradiation at a dose of 10 Gy, the distribution of γ-H2AX foci was visualized by immunofluorescence staining (n = 3 per group). The cell nuclei were counter-stained with DAPI (blue). Scale bars, 20 µm. (**d**) Volcano plot shows DEGs between C666 bulk samples (left) and RT sh-ITGA2 C666 bulk sample (right). The names of the reported irradiation-resistance related TFs are indicated in the plot1-6. (**e**) Correlation between the expression of TFs which highly expressed in C666 bulk samples and the cell score for FAK-PI3K\_AKT in single malignant cells. Two-sided Spearman’s correlation test. (**f**) Enrichment of the TFs that are highly expressed in C666 bulk samples (versus sh-ITGA2 C666). (**g**) C666 cells combined with MCAM+ mCAFs (3:1) were injected subcutaneously into NCG mice (n = 6 per group). The mice were randomly subjected to gavage with MK2206 or DMSO, and treated with radiotherapy at a dose of 2 Gy for 5 consecutive days. (**h**) The deconvolution score of malignant and the score of the TGF-β pathway in malignant spots based on the ST data. Scale bars, 500 µm. (**i**) Violin plots showing the TGF-β score in malignant cells from PT (blue, n = 3,241) and RT (red, n = 11,105) samples based on the scRNA-seq data. Two-sided Wilcoxon rank-sum test. (**j**) Boxplot showing the TGF-β scores of NPC cells from wild type (W) and radioresistant tumor cells (R) based on the bulk RNA seq data (n = 3 per group). One-sided paired _t_\-test. (**k**) Western blotting for key proteins in MCAM− CAFs after being treated with recombinant TGF-β in different concentration gradients. (**l**) MTT assay was performed after MCAM− mCAFs cells were treated with increasing doses of TGF-β. Two-sided ANOVA test.

[Source data](https://www.nature.com/articles/s41588-025-02253-8#MOESM15)

### [Extended Data Fig. 6 The construction and validation of HuHSC-NCG mice, related to Fig.](https://www.nature.com/articles/s41588-025-02253-8/figures/14) [5](https://www.nature.com/articles/s41588-025-02253-8#Fig5).

(**a**) Schematic illustration of the construction process of the humanized mouse model. (**b**) After establishing the humanized mouse model, the percentage of mCD45 cells, hCD45 cells, hCD19 cells, and hCD3 cells among PBMC was detected in 18 of the mouse models by flow cytometry. (**c**) Western blotting for the expression of Col4a1 in MCAM+ CAFs and Col4a1 knockout MCAM+ CAFs. (**d**) Scatter plot showing the correlations between the expression level of _COL4A1_ and the ratio of CD8+ T, and CD4+ T cells in spatial data. Two-sided Spearman’s correlation test. (**e**) C666 cells (1×106) were combined with MCAM+ mCAFs with or without COL4A1 KO and injected subcutaneously into HuHSC-NCG mice followed by irradiation (n = 5 per group). Box plot showing the ratio of CD8+T cells and subgroups of CD8+ T cells in the tumor mice using flow cytometry. Two-sided _t_\-test.

[Source data](https://www.nature.com/articles/s41588-025-02253-8#MOESM16)

### [Extended Data Fig. 7 CD8+ T cells maintain a memory phenotype with weak cytotoxicity in rNPC, related to Fig.](https://www.nature.com/articles/s41588-025-02253-8/figures/15) [6](https://www.nature.com/articles/s41588-025-02253-8#Fig6).

(**a**) Heatmap showing the expression of marker genes for each cluster defined in Fig. [6a](https://www.nature.com/articles/s41588-025-02253-8#Fig6). (**b**) Heatmap indicating the expression of selected gene sets in T/NK subtypes, including naive, resident, inhibitory, cytokines, co-stimulatory, transcriptional factors (TF), and cell type. (**c**) Boxplots illustrating the ratios of NK subtypes in PT (blue) and RT (red) tumors, respectively. Two-sided Wilcoxon rank-sum test. (**d**) UMAP plot showing the gene sets for CD8+ T cells, including naive, cytotoxic, and exhausted. (**e**) Tree map showing the correspondence between the subtypes of CD8+ T cells and other functional CD8+ T cell types of including naive, cytotoxic, and exhausted. (**f**) Pseudotime-ordered analysis of CD8+ T cells from pNPC and rNPC samples. UMAP plots are labeled by pseudotime (left panel), as well as the naive, cytotoxic, and exhausted CD8+ cell types (right panel). (**g**) Negative gates of ZNF683 and granzyme B in FACS assays.

### [Extended Data Fig. 8 Tertiary lymphoid structures are depleted in rNPC, related to Fig.](https://www.nature.com/articles/s41588-025-02253-8/figures/16) [7](https://www.nature.com/articles/s41588-025-02253-8#Fig7).

(**a**\-**b**) Violin plots showing the percentages of various immune-cell types in TLS (green) and other tissues (orange) in two representative patients. Two-sided Wilcoxon rank-sum test. (**c**\-**d**) Violin plots showing the percentages of B, CD4+ T, and CD8+ T cell subclusters in TLS (green) and other tissues (orange) in two representative patients. Two-sided Wilcoxon rank-sum test. (**e**\-**f**) Kaplan-Meier analysis showing the PFS of patients from validation cohort 4, stratified by low (green) or high (blue) expression of _MS4A1_ (**n**) and _BANK1_ (**o**). Two-sided log-rank test. (**g**) Kaplan-Meier analysis showing the PFS of patients from validation cohort 4, stratified by low (green) or high (blue) ratio of B cells. Two-sided log-rank test.

### [Extended Data Fig. 9 SIRPα+ myeloid cells reside near CD47+ malignant cells to inhibit antigen-presentation in rNPC, related to Fig.](https://www.nature.com/articles/s41588-025-02253-8/figures/17) [8](https://www.nature.com/articles/s41588-025-02253-8#Fig8).

(**a**) UMAP plot showing myeloid cells, color-coded according to PT (blue) and RT (red). (**b**) t-SNE plot showing the expression of marker genes for the identification of the indicated cell subtypes in Fig. [8a](https://www.nature.com/articles/s41588-025-02253-8#Fig8). (**c**) Scatterplots showing M1 and M2 scores (left panel), as well as pro- and anti-inflammatory scores (right panel) for each color-coded macrophage subtypes. (**d**) Colocalization scores of TME cells to malignant cells in PT (left) and RT (right). (**e**) Differences in colocalization scores of TME cells to malignant cells between PT and RT samples. (**f**) Bar chart showing the number of significant LR interactions from malignant to myeloid subtypes in PT (blue) and RT (red) samples. (**g**) Scatterplot showing the association between the expression of _SIRPA_ in myeloid subtypes and the distance of these subclusters to CD47+ malignant cells in PT samples, inferred from spatial transcriptomics (ST). Two-sided Spearman’s correlation test.

### [Extended Data Fig. 10](https://www.nature.com/articles/s41588-025-02253-8/figures/18)

Schematic diagram of the mechanism of radioresistance and immune escape in rNPC and potential targeted treatment strategies.

Supplementary information
-------------------------

### [Supplementary Information](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM1_ESM.pdf)

Supplementary Notes 1–13, Supplementary Figs. 1–4 and References.

### [Reporting Summary](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM2_ESM.pdf)

### [Peer Review File](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM3_ESM.pdf)

### [Supplementary Tables 1–7](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM4_ESM.xlsx)

1\. Clinical information for cohort. **a**, Clinical information of patients in discovery cohort 1. **b**, Clinical information of patients in validation cohort 1. **c**, Clinical information of patients in validation cohort 2. 2. All the relevant gene sets used in the current study. 3. Multivariate analysis of the proportions of MCAM+ mCAFs and other clinical characteristics in LRRFS and overall survival. 4. Communication _P_ value and neighborhood enrichment score on spatial transcriptomics data. 5. The proportions and count of leukocytes in the humanized mouse model. 6. The comparison of the percentages of cell types and subtypes in TLS versus other tissues. 7. Relevant sequence used in this article. **a**, The RT–qPCR sequence for Notch3, Sox4, Atf3, Col4a1, Sox9, and Mcam. **b**, The siRNA sequence for Notch3, Sox9, Atf2, Atf3, Notch3, Sox4. **c**, The shRNA sequence for Itga2, Col4a1.

Source data
-----------

### [Source Data Fig. 1](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM5_ESM.pdf)

Unprocessed western blots.

### [Source Data Fig. 3](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM6_ESM.xlsx)

Source Data from biological experiments.

### [Source Data Fig. 4](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM7_ESM.xlsx)

Source Data from biological experiments.

### [Source Data Fig. 5](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM8_ESM.xlsx)

Source Data from biological experiments.

### [Source Data Fig. 6](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM9_ESM.xlsx)

Source Data from biological experiments.

### [Source Data Fig. 7](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM10_ESM.xlsx)

Source Data from biological experiments.

### [Source Data Fig. 8](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM11_ESM.xlsx)

Source Data from biological experiments.

### [Source Data Extended Data Fig. 2](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM12_ESM.xlsx)

Source Data from biological experiments.

### [Source Data Extended Data Fig. 3](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM13_ESM.xlsx)

Source Data from biological experiments.

### [Source Data Extended Data Fig. 4](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM14_ESM.xlsx)

Source Data from biological experiments.

### [Source Data Extended Data Fig. 5](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM15_ESM.xlsx)

Source Data from biological experiments.

### [Source Data Extended Data Fig. 6](https://static-content.springer.com/esm/art%3A10.1038%2Fs41588-025-02253-8/MediaObjects/41588_2025_2253_MOESM16_ESM.xlsx)

Source Data from biological experiments.

Rights and permissions
----------------------

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

[Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=Single-cell%20and%20spatial%20transcriptomics%20reveal%20mechanisms%20of%20radioresistance%20and%20immune%20escape%20in%20recurrent%20nasopharyngeal%20carcinoma&author=Rui%20You%20et%20al&contentID=10.1038%2Fs41588-025-02253-8&copyright=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer%20Nature%20America%2C%20Inc.&publication=1061-4036&publicationDate=2025-07-21&publisherName=SpringerNature&orderBeanReset=true)

About this article
------------------

[![Check for updates. Verify currency and authenticity via CrossMark](data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>)](https://crossmark.crossref.org/dialog/?doi=10.1038/s41588-025-02253-8)

### Cite this article

You, R., Shen, Q., Lin, C. _et al._ Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma. _Nat Genet_ **57**, 1950–1965 (2025). https://doi.org/10.1038/s41588-025-02253-8

[Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41588-025-02253-8?format=refman&flavour=citation)

-   Received: 15 December 2023
    
-   Accepted: 02 June 2025
    
-   Published: 21 July 2025
    
-   Issue Date: August 2025
    
-   DOI: https://doi.org/10.1038/s41588-025-02253-8
    

### Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative
